Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Sep 30, 2023 | (FY)Sep 30, 2022 | |
---|---|---|
Total revenue | 5.05%3.34B | 3.18B |
Cost of revenue | 0.27%1.48B | 1.47B |
Gross profit | 9.18%1.86B | 1.7B |
Operating expense | 5.75%1.78B | 1.68B |
Operating profit | 302.66%79.28M | 19.69M |
Net non-operating interest income (expenses) | -18K | 0 |
Non-operating interest income | --0 | --0 |
Non-operating interest expense | --18K | --0 |
Net investment income | 13.51%42K | 37K |
Gain(Loss) on financial instruments designated as cash flow hedges | ||
Gain(Loss) on derecognition of available-for-sale financial assets | ||
Income from associates and other participating interests | ||
Special income (charges) | -761.74%-28.65M | -3.33M |
Less:Impairment of capital assets | 3,156.88%27.94M | --858K |
Less:Other special charges | -71.26%709K | --2.47M |
Other non-operating income (expenses) | -90.16%584K | 5.93M |
Income before tax | 129.41%51.24M | 22.34M |
Income tax | 156.13%8.02M | -14.29M |
Net income | 18.00%43.22M | 36.62M |
Net income continuous operations | 18.00%43.22M | --36.62M |
Noncontrolling interests | ||
Net income attributable to the company | 18.00%43.22M | 36.63M |
Preferred stock dividends | ||
Other under preferred stock dividend | 0 | 0 |
Net income attributable to common stockholders | 18.00%43.22M | 36.63M |
Gross dividend payment | ||
Basic earnings per share | 18.00%21.608 | 18.3125 |
Diluted earnings per share | 18.00%21.608 | 18.3125 |
Dividend per share | ||
Currency Unit | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP |